This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius signing a US$ 322M deal with Sandoz, and KeyMed proposing a STAR Market listing. Clinical highlights feature Sunshine Guojian’s NMPA approval for anflekitug, RemeGen’s RC148…

Five conferences, five continents’ worth of anxiety, one unmistakable pattern: the global pharma industry is being reshaped faster than it can keep up. From Philadelphia to Geneva, Istanbul to Chicago to London, the Shawview Consulting team found the same threads running through every panel and corridor conversation — AI and real-world data racing ahead of…

Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors through the data gaps, bridging studies, and regulatory quirks that stand between a China-developed drug and a Western marketing authorisation. She spoke with DIA’s Global…

Affordability and innovation are usually framed as a zero-sum trade-off in drug pricing debates. Zeba M. Khan, editor-in-chief of ISPOR’s Value & Outcomes Spotlight magazine, makes the case that they don’t have to be — if pricing policy is grounded in evidence rather than blunt instruments. Khan walks through the IRA’s Medicare reforms, the ripple…